Mar 23 |
We Think Entera Bio (NASDAQ:ENTX) Can Afford To Drive Business Growth
|
Mar 20 |
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
|
Mar 8 |
Entera Bio GAAP EPS of -$0.31 beats by $0.01
|
Mar 8 |
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
|
Mar 4 |
Entera Bio regains compliance with Nasdaq minimum bid price requirement
|
Mar 4 |
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
Feb 2 |
Entera Bio files to sell 16.5M ordinary shares for holders
|
Jan 12 |
Entera Bio And 3 Other Stocks Under $1 Insiders Are Buying
|